Intrahepatic Cholangiocarcinoma

CLINICAL_TRIALS trial_result · 2023-04-21

Clinical Trial Update: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer [NA]

Clinical trial update for M5A, a Copper-64 labeled anti-CEA monoclonal antibody used in PET imaging to diagnose CEA-positive cancers; the st…

CLINICAL_TRIALS trial_result · 2023-04-19

Clinical Trial Update: Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study [Phase 2]

Phase II single-arm trial evaluating camrelizumab with apatinib for advanced intrahepatic cholangiocarcinoma.

CLINICAL_TRIALS trial_result · 2023-04-13

Clinical Trial Update: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 trial update exploring HAIC with sintilimab and bevacizumab for unresectable intrahepatic cholangiocarcinoma.

CLINICAL_TRIALS trial_result · 2023-03-31

Clinical Trial Update: Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 trial evaluating the combination of durvalumab and SNDX-6532 after chemotherapy or radioembolization in patients with unresectable i…

CLINICAL_TRIALS trial_result · 2023-01-25

Clinical Trial Update: A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation [Phase 1, Phase 2]

Phase 1/2 trial evaluating FT-2102 in IDH1-mutant advanced solid tumors and gliomas; study completed with posted results.

CLINICAL_TRIALS trial_result · 2023-01-05

Clinical Trial Update: Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk [Phase 2]

Phase 2 trial evaluating durvalumab in combination with gemcitabine/cisplatin neoadjuvant therapy for resectable intrahepatic cholangiocarci…

CLINICAL_TRIALS trial_result · 2022-11-17

Clinical Trial Update: Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. [Phase 2]

Phase 2 trial comparing tislelizumab plus lenvatinib and GEMOX versus tislelizumab plus GEMOX for conversion therapy in potentially resectab…

CLINICAL_TRIALS trial_result · 2022-09-10

Clinical Trial Update: Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 clinical trial update on second-line therapy for advanced intrahepatic cholangiocarcinoma.

CLINICAL_TRIALS trial_result · 2022-08-18

Clinical Trial Update: Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence [Phase 1, Phase 2]

A clinical trial exploring adjuvant PD-1 antibody in combination with capecitabine for intrahepatic cholangiocarcinoma at high risk of recur…

CLINICAL_TRIALS trial_result · 2022-08-05

Clinical Trial Update: HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 trial investigating HAIC with tislelizumab and apatinib for unresectable intrahepatic cholangiocarcinoma is ongoing; current status …

CLINICAL_TRIALS trial_result · 2022-03-24

Clinical Trial Update: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma [Phase 2, Phase 3]

Clinical trial update comparing Percutaneous Hepatic Perfusion to Cisplatin/Gemcitabine in intrahepatic cholangiocarcinoma (bile duct cancer…

CLINICAL_TRIALS trial_result · 2022-02-23

Clinical Trial Update: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 trial update evaluating sintilimab with GEMOX ± IBI305 (bevacizumab biosimilar) versus GEMOX in advanced intrahepatic cholangiocarci…

CLINICAL_TRIALS trial_result · 2022-02-02

Clinical Trial Update: Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers [Phase 2]

Phase 2 trial evaluating gemcitabine hydrochloride, cisplatin, and nab-paclitaxel for advanced or metastatic biliary cancers has completed w…

CLINICAL_TRIALS trial_result · 2022-01-13

Clinical Trial Update: Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin [Phase 2]

A Phase 2 clinical trial evaluating irinotecan-eluting beads with gemcitabine and cisplatin or carboplatin for unresectable intrahepatic cho…

CLINICAL_TRIALS trial_result · 2021-07-14

Clinical Trial Update: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC [Phase 3]

Phase 3 trial comparing hepatic arterial infusion chemotherapy with FOLFOX to systemic GP chemotherapy for unresectable intrahepatic cholang…

CLINICAL_TRIALS trial_result · 2021-07-14

Clinical Trial Update: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 trial investigating toripalimab plus gemox as first-line therapy for intrahepatic cholangiocarcinoma is reported as ongoing with unk…

CLINICAL_TRIALS trial_result · 2021-07-07

Clinical Trial Update: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 clinical trial investigating a combination of oxaliplatin and gemcitabine chemotherapy, lenvatinib, and a PD-1 antibody (JS001) for …

CLINICAL_TRIALS trial_result · 2021-02-25

Clinical Trial Update: Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis [Phase 2]

Phase 2 trial evaluating systemic chemotherapy with lenvatinib plus sintilimab for intrahepatic cholangiocarcinoma with distant metastasis i…

CLINICAL_TRIALS trial_result · 2020-12-02

Clinical Trial Update: A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 study assessing second-line apatinib in advanced intrahepatic cholangiocarcinoma has completed.

CLINICAL_TRIALS trial_result · 2020-08-26

Clinical Trial Update: Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

A Phase 2 trial evaluating cisplatin and gemcitabine chemotherapy combined with lenvatinib for unresectable intrahepatic cholangiocarcinoma …

CLINICAL_TRIALS trial_result · 2020-08-21

Clinical Trial Update: Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis [Phase 2]

A Phase 2 trial update on neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma with high risk of lymph node metastasis.

CLINICAL_TRIALS trial_result · 2020-08-10

Clinical Trial Update: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors [Phase 2]

Phase 2 trial evaluating neoadjuvant therapy with a PD-1 antibody (toripalimab), GEMOX chemotherapy, and lenvatinib for resectable intrahepa…

CLINICAL_TRIALS trial_result · 2020-07-31

Clinical Trial Update: Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

Phase II trial investigating dasatinib in IDH-mutant advanced intrahepatic cholangiocarcinoma has completed with posted results.

CLINICAL_TRIALS trial_result · 2020-06-04

Clinical Trial Update: Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

Phase 2 trial update on combining an anti-PD-1 antibody with chemotherapy for unresectable intrahepatic cholangiocarcinoma.

CLINICAL_TRIALS trial_result · 2020-03-03

Clinical Trial Update: Stereotactic Body Radiotherapy for Liver Tumors [NA]

Clinical trial update on stereotactic body radiotherapy for liver tumors has completed with posted results.

Top drugs studied for this disease